Ildar Nurmeev

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial

Christoph Male, Anthonie W.A. Lensing, Joseph S. Palumbo et al. · The Lancet Haematology · 2019 · 294 citations · Full text

Pulmonary Embolism, Thrombosis, Venous Thrombosis +9

Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial

Leonardo R. Brandão, Matteo Luciani, Lisa Bomgaars et al. · The Lancet Haematology · 2020 · 134 citations · Full text

Thrombosis, Venous Disease, Venous Thrombosis +8

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

Leonardo R. Brandão, Manuela Albisetti, Lisa Bomgaars et al. · Blood · 2019 · 90 citations · Full text

Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation

Guy Young, Anthonie W.A. Lensing, Paul Monagle et al. · Journal of Thrombosis and Haemostasis · 2020 · 80 citations · Full text

Thrombosis, Venous Disease, Venous Thrombosis +9

Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)

Katharina Thom, Anthonie W.A. Lensing, Ildar Nurmeev et al. · Blood Advances · 2020 · 49 citations · Full text